News

  • October 2026

    TremeBio was selected as one of 16 finalists from over 100 applications for the pitch competition at the 2026 BioFlorida Innovation Conference. The event brought together emerging life sciences companies, investors, and industry leaders to showcase innovative technologies and new therapeutic approaches. TremeBio presented its ProLymphNano drug delivery platform and its potential to advance medicines targeting the lymphatic system.

  • August 2026

    TremeBio was selected as the winner of the 2026 Georgia Life Sciences Startup Showcase, sponsored by Johnson & Johnson. The Showcase highlighted eight of Georgia's most promising early-stage life sciences companies, with participants presenting their technologies to an audience of industry leaders, investors, researchers, and strategic partners.

    As the selected company, TremeBio will also participate in the NewYorkBIO / New York Stock Exchange Life Sciences Showcase on December 10 in New York City. The event brings together emerging therapeutics companies with members of the financial and investment community, providing TremeBio an opportunity to share its work advancing the next generation of lymphatic medicines with a broader life sciences audience.

  • April 2026

    TremeBio joined patients, advocates, researchers, and other members of the lymphatic disease community in Washington, D.C. for Advocacy Day hosted by the Lymphatic Education & Research Network (LE&RN), a global organization dedicated to advancing the fight against lymphedema and lymphatic diseases.

    The event brought the community together on Capitol Hill to raise awareness of the significant burden of lymphatic diseases and advocate for greater research, education, and access to care. For TremeBio, the opportunity to engage directly with patients and advocates reinforced the need for new therapeutic approaches and our commitment to advancing medicines for diseases of the lymphatic system.

  • March 2026

    TremeBio launched to develop innovative drug delivery technologies for diseases of the lymphatic and immune systems. The company is serving as the commercialization partner to Georgia Tech on its HEAL project, supported by an award of up to $21.8 million from the Advanced Research Projects Agency for Health (ARPA-H).

    The project is part of ARPA-H's Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program, a major initiative focused on developing new therapeutic approaches that directly target the lymphatic system. Together with Georgia Tech and a multidisciplinary team of collaborators, TremeBio is working to translate innovative lymphatic drug delivery technologies toward the clinic.